Incentive Spirometer Training in Type 2 Diabetes With Sarcopenia
NCT ID: NCT06500221
Last Updated: 2024-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
45 participants
INTERVENTIONAL
2024-08-01
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Effects of Inspiratory Muscle Exercise on Glucose Level and Glucose Variability in Patients With Type 2 Diabetes.
NCT02292810
Respiratory Training Intervention
NCT05969678
Inspiratory Muscle Training on Glycemic Control in Individuals With Type 2 Diabetes
NCT03191435
Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness
NCT00815178
Investigation of Respiratory Muscle Sarcopenia in Adults Diagnosed With Diabetes
NCT07002333
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The inclusion criteria:
1. Diagnosed with Type 2 diabetes (ICD-10 diagnosis codes: E10.x or E11.x)
2. Screened with a score of 4 or above on the screening self-administered sarcopenia (SARC-F) questionnaire.
3. Aged between 20-90 years old and able to communicate in Mandarin or Taiwanese
The exclusion criteria:
1. Patients with a functional status grade of ≥5 on the Modified Rankin Scale (MRS), indicating severe disability or bedridden condition.
2. Patients suffering from dementia, such as Alzheimer's disease, Parkinson's disease, etc.
3. Patients with acute psychiatric symptoms unable to communicate.
4. Currently diagnosed with chronic obstructive pulmonary disease (COPD) or any other respiratory system diseases.
5. Moderate or severe heart disease (New York Heart Association functional classification Class III or IV).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Type 2 diabetes combined with sarcopenia
incentive spirometry intervention
incentive spirometry
The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
Type 2 diabetes combined with sarcopenia control
Routine care.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
incentive spirometry
The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Screened with a score of 4 or above on the SARC-F questionnaire.
* Aged between 20-90 years old and able to communicate in Mandarin or Taiwanese
Exclusion Criteria
* Patients suffering from dementia, such as Alzheimer\'s disease, Parkinson\'s disease, etc.
* Patients with acute psychiatric symptoms unable to communicate.
* Currently diagnosed with chronic obstructive pulmonary disease (COPD) or any other respiratory system diseases.
* Moderate or severe heart disease (New York Heart Association functional classification Class III or IV).
20 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yu-Shan Hsieh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yu-Shan Hsieh
Associate professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N202404019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.